Increasing clinical data suggests that in a majority of cancer patients, the use of PD-1 or PD-L1 antibody treatments can induce diabetic ketoacidosis (DKA) or trigger acute onset of type 1 diabetes shortly after initiation, significantly reducing the clinical efficacy of antitumor therapies [48, 49] Therefore, based on the above research and case analysis, we know that tumors associated with autoimmune diabetes have no advantage during immunotherapy. The gene discussed is PDCD1; the disease is type 1 diabetes mellitus.